# CureVac

mRNA therapeutics pioneer acquired by BioNTech (Jan 2025) — CV8102 adjuvant and thermostable mRNA formulation technology for vaccines and oncology.

Source: https://en.bioecon.ru/companies/curevac/
Updated: 2026-06-19

- Country: Germany
- Revenue: ~$50M
- Employees: ~200 emp

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | €438.3 million cash position as of March 31, 2025; €481.7 million cash position as of December 31, 2024 | https://www.curevac.com/wp-content/uploads/2025/04/20250410-CureVac-Investor-Handout.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250410-PR-CureVac-Q4-FY-Results-EN.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250417_CureVac-Transcript-Financial-Results-Fourth-Quarter-and-Full-Year-2024.pdf, https://www.curevac.com/wp-content/uploads/2025/05/20250520-CureVac-Investor-Handout.pdf |
| Production site | Tübingen, Germany (headquarters and manufacturing), with additional operations in the Netherlands, Belgium, Switzerland, and the U.S. | https://synapse.patsnap.com/article/what-is-the-research-and-development-focus-of-curevac, https://www.curevac.com/wp-content/uploads/2025/04/20250410-CureVac-Investor-Handout.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250410-PR-CureVac-Q4-FY-Results-EN.pdf, https://www.curevac.com/wp-content/uploads/2025/05/CureVac-N.V._Dutch-Board-Report-Independent-Auditors-Report-FY2024-signed.pdf |
| Certification | Manufacturing license for mRNA construct (Nov 2023), drug substance framework manufacturing license (Dec 2023), and updated manufacturing license for oncology (July 2024) for The RNA Printer® | https://www.curevac.com/wp-content/uploads/2025/05/CureVac-N.V._Dutch-Board-Report-Independent-Auditors-Report-FY2024-signed.pdf |
| Revenue | €535.2 million for the full year 2024; €14.5 million for the fourth quarter of 2024 | https://www.curevac.com/wp-content/uploads/2025/04/20250410-CureVac-Investor-Handout.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250410-PR-CureVac-Q4-FY-Results-EN.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250417_CureVac-Transcript-Financial-Results-Fourth-Quarter-and-Full-Year-2024.pdf, https://www.curevac.com/wp-content/uploads/2025/05/CureVac-N.V._Dutch-Board-Report-Independent-Auditors-Report-FY2024-signed.pdf |
| Headcount | Approximate average workforce of 1,088 over 2024; company completed a 30% workforce reduction in 2024 | https://www.curevac.com/wp-content/uploads/2025/04/20250410-CV-Q4-FY-Earnings-Call-presentation.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250410-CureVac-Investor-Handout.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250417_CureVac-Transcript-Financial-Results-Fourth-Quarter-and-Full-Year-2024.pdf, https://www.curevac.com/wp-content/uploads/2025/05/20250520-CureVac-Investor-Handout.pdf, https://www.curevac.com/wp-content/uploads/2025/05/CureVac-N.V._Dutch-Board-Report-Independent-Auditors-Report-FY2024-signed.pdf |
| Capacity | Deprioritized commercial large-scale manufacturing; focus on small-scale clinical trial supply using The RNA Printer® and existing GMP facilities (GMP III + GMP IV) | https://www.curevac.com/wp-content/uploads/2025/04/20250410-CureVac-Investor-Handout.pdf, https://www.curevac.com/wp-content/uploads/2025/04/20250410-PR-CureVac-Q4-FY-Results-EN.pdf, https://www.curevac.com/wp-content/uploads/2025/05/CureVac-N.V._Dutch-Board-Report-Independent-Auditors-Report-FY2024-signed.pdf |

Independent sources: synapse.patsnap.com

## Technologies

- [mRNA platforms & LNP delivery](https://en.bioecon.ru/technology/mrna-platforms-lnp-delivery/)